HAPLOIDENTICAL HEMOPOIETIC STEM CELL TRANSPLANTATION
====================================================

For over 40 years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an human leukocyte antigen (HLA)-matched donor, either related or unrelated, has been increasingly used to treat patients affected by several malignant or non-malignant disorders. Thanks to this procedure, thousands of subjects have been cured of their original disease ([@B20]). However, only 25% of patients who need an allograft have an HLA-identical sibling available and for \<60% of the remaining patients a suitable, HLA-compatible, unrelated volunteer can be found ([@B64]). In the absence of an HLA-matched donor, alternative donors/sources of hematopoietic stem cells (HSC), such as unrelated umbilical cord blood (UCB) and HLA-haploidentical relatives, are being increasingly used ([@B26]; [@B64]; [@B35]). In particular, the majority of patients have a family member, identical for one HLA-haplotype and fully mismatched for the other (i.e., haploidentical), who can immediately serve as HSC donor ([@B38]; [@B35]). Thus, HSCT from an HLA-haploidentical relative (haplo-HSCT) offers an immediate transplant treatment *virtually* to *any* patients lacking a matched donor or a suitable UCB unit.

A major breakthrough in the history of successful haplo-HSCT was the demonstration that an efficient T cell-depletion of the graft prevented both acute and chronic graft-vs-host disease (GvHD), even when the donor was a relative differing for an entire HLA-haplotype from the recipient ([@B61]). The importance of T cell-depleted haplo-HSCT was first shown in children with severe combined immunodeficiency (SCID; [@B61]) and it can now be estimated that hundreds of SCID patients have been transplanted worldwide using an HLA-haploidentical related donor, with a high rate of long-term, either partial or complete, immune reconstitution ([@B1]). However, while the infusion of bone marrow (BM) cells obtained from an HLA-haploidentical relative was associated with a high engraftment rate in children with SCID, it was associated with an unacceptably high incidence of graft failure in patients with acute leukemia ([@B62]). In these cases, due to the extensive T cell-depletion of the graft, the balance between competing host and donor T cells shifts in favor of the unopposed host-vs-graft rejection ([@B62]). As a possible solution to this obstacle, the use of "megadoses" of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood-derived HSC was shown, in animal models, to overcome the barrier of HLA incompatibility and to elude the residual anti-donor T lymphocyte reactivity of the recipient ([@B5]). An effective translation of this approach into the clinical setting was first reported in a pilot study performed in adults with acute leukemia ([@B3]). In this study, [@B3] transplanted "megadoses" of T cell-depleted HSC from BM or G-CSF-mobilized peripheral blood without any subsequent pharmacological GvHD prophylaxis. The reported engraftment rate was above 90% with a cumulative incidence of both grade II--IV acute and chronic GvHD below 10%. Clinical trials performed using purified CD34^+^ cells have confirmed that sustained engraftment of donor hematopoiesis, without the occurrence of GvHD, can be obtained in the majority of adult patients and that a substantial proportion of them, especially when affected by acute myeloid leukemia (AML) or myelodysplastic syndromes, become long-term survivors ([@B4]; [@B67]).

In view of the role played by donor T cells in mediating the graft-vs-leukemia (GvL) effect, it could be expected that a relevant proportion of patients given this type of allograft would experience leukemia relapses. This expectation was only partly confirmed by clinical results, since among adult patients affected by AML, a subgroup of patients given T cell-depleted HSCT from an HLA-disparate relative had a particularly low risk of leukemia relapse ([@B4]; [@B67]). These patients were transplanted from a donor having natural killer (NK) cells that were "alloreactive" toward recipient targets. NK cell alloreactivity was originally described by [@B42] over 20 years ago when killing of allogeneic lymphoblasts was observed *in vitro* and associated with defined NK cell subsets ([@B42]) identified by the expression or lack thereof of novel surface molecules ([@B43]), subsequently identified as HLA class I-specific receptors ([@B15], [@B16]; [@B48], [@B45]; [@B79]). The emergence of the concept of the efficacy of NK cell alloreactivity in this transplantation setting has represented a sort of revolution in the field of haplo-HSCT, underlining for the first time that not only adaptive immunity, but also innate immunity is a crucial element for guaranteeing a successful clinical outcome ([@B46]; [@B35]). Indeed, it became evident that the therapeutic effect of haplo-HSCT is largely dependent on the GvL effect exerted by NK cells which originate from donor HSC ([@B67]; [@B46]; [@B35]) and largely contribute to eradicate leukemia cells surviving the preparative regimen.

Thus, while for many years the absence of the T cell-mediated GvL effect was considered to render the recipients of a T cell-depleted allograft more susceptible to leukemia relapse ([@B31]), it is now evident that, in haplo-HSCT, an efficient GvL effect can be mediated by donor-derived alloreactive NK cells which compensate for the lack of T cell intervention.

NK CELL RECEPTORS AND FUNCTION
==============================

Natural killer cells are important players of the innate immunity. They are regulated by a number of receptors that finely tune potent effector functions, including cytolytic activity against different target cells and release of cytokines that play a major role in inflammation and immunoregulation ([@B74]; [@B50]; [@B32]; [@B52]).

A group of inhibitory receptors interact specifically with major histocompatibility (MHC) class I molecules ([@B15]; [@B48], [@B45]; [@B36]). These receptors prevent NK cell-mediated attack against normal (i.e., MHC class I^+^) autologous cells. Cells in which MHC class I expression is compromised/downregulated (e.g., by tumor transformation or viral infection) become susceptible to NK-mediated killing. In humans, the inhibitory receptors for HLA class I molecules, namely: (1) killer immunoglobulin (Ig)-like receptors (KIR2DL/3DL) that belong to the Ig superfamily and are specific for determinants shared by groups of HLA-A, -B, or -C allotypes (referred to as KIR-ligands; reviewed in [@B45]; [@B33]; [@B36]; **Table [1](#T1){ref-type="table"}**), (2) CD94/NKG2A, a heterodimer related to C-type lectins that recognizes HLA-E, an HLA class Ib molecule ([@B33]; [@B37]), and (3) LILRB1 (ILT2, LIR-1, CD85j) that displays broad HLA class I specificity and interacts with UL18 human cytomegalovirus (HCMV) glycoprotein ([@B17]; [@B21]). Notably, activating forms of KIRs (KIR2DS/3DS; [@B47], [@B45]; [@B33]), and CD94/NKG2C also exist. Activating KIRs may be relevant for recognition and killing of leukemia cells and dendritic cells (DCs; see below), while CD94/NKG2C appears to be involved in the control of HCMV infections ([@B28]; [@B23]; [@B25]). In addition, NK cells are equipped with several triggering receptors responsible for NK cell activation in the process of natural cytotoxicity. An important role in tumor cell killing is exerted by NKp46 ([@B70]; [@B58]), NKp30 ([@B56]), and NKp44 ([@B77]; [@B11]), a group of activating receptors that are mostly restricted to NK cells and that are collectively named "natural cytotoxicity receptors" (NCRs). In particular, NKp46 expressed both in human and in mouse NK cells represents the most reliable marker for NK cell identification ([@B70]; [@B80]). The cellular ligands recognized by these receptors are still elusive, with the exception of B7-H6, a ligand for NKp30 ([@B10]). Another receptor that plays a major role in NK cell-mediated recognition and killing of some tumors is NKG2D, a type II membrane protein characterized by a lectin-like domain ([@B82]). NKG2D recognizes the stress-inducible MHC class I-related chain A/B (MICA/B) or UL16-binding proteins (ULBP; [@B60]). Other activating receptors include 2B4 ([@B44]; [@B76]) specific for CD48, NK, T, and B cell antigen (NTB-A; [@B9]) mediating homotypic interactions, NKp80 ([@B78]) specific for AICL1 ([@B81]), DNAM-1 ([@B68]) specific for poliovirus receptor (PVR, CD155), and Nectin-2 (CD112; [@B8]) also involved in cell-to-cell adhesion and in leukocyte extravasation ([@B63]). Notably, PVR and Nectin-2 are frequently over-expressed on tumor cells and leukemia blasts ([@B8]). Recognition of self-ligands that are induced by viral infection, tumor transformation, and in general cell stress may represent an important mechanism by which NK cells can identify and remove abnormal cells.

###### 

KIRs and KIR-ligands.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  KIR         Domain composition   KIR-ligand                                                                                           Function                                                Reference
  ----------- -------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------- -----------------------
  2DL1        D1 + D2              HLA-C^Lys80^ (C2)                                                                                    Inhibitory                                              [@B14], [@B7]

  2DL2/2DL3   D1 + D2              HLA-C^Asn80^ (C1), HLA-B[\*](#T1fn01){ref-type="fn"}46:01, HLA-B[\*](#T1fn01){ref-type="fn"}73:01\   Inhibitory                                              [@B14], [@B7], [@B41]
                                   Low affinity: HLA-C^Lys80^ (C2)                                                                                                                              

  2DL4        D0 + D2              HLA-G                                                                                                Inhibitory and activating[\*](#T1fn01){ref-type="fn"}   [@B59]

  2DL5        D0 + D2              Unknown                                                                                              Inhibitory                                              

  3DL1        D0 + D1 + D2         HLA-B^Bw4^ and some HLA-A^Bw4^                                                                       Inhibitory                                              [@B29], [@B71]

  3DL2        D0 + D1 + D2         HLA-A[\*](#T1fn01){ref-type="fn"}03 and HLA-A[\*](#T1fn01){ref-type="fn"}11                          Inhibitory                                              [@B24], [@B54]

  2DS1        D1 + D2              HLA-C^Lys80^ (C2)                                                                                    Activating                                              [@B72], [@B13]

  2DS2        D1 + D2              Unknown                                                                                              Activating                                              

  2DS3        D1 + D2              Unknown                                                                                              Activating                                              

  2DS4        D1 + D2              HLA-A[\*](#T1fn01){ref-type="fn"}11 and some HLA-C alleles                                           Activating                                              [@B27]

  2DS5        D1 + D2              Unknown                                                                                              Activating                                              

  3DS1        D0 + D1 + D2         HLA-B^Bw4^ (?)                                                                                       Activating                                              [@B39]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*KIR2DL4 may function as an inhibitory receptor in cytotoxicity while it triggers IFN-γ production*.

KIR REPERTOIRE AND SPECIFICITY FOR HLA CLASS I ALLELES
======================================================

The ability of NK cells to sense allelic differences on hematopoietic target cells was first suggested by the hybrid resistance phenomenon in which NK cells can reject parental BM grafts in F1 hybrid mice ([@B6]). Studies in both humans and mice clarified the general mechanisms underlying NK cell function and their capability of selectively killing tumor cells. In humans, two surface molecules expressed by subsets of NK cells that were capable of modulating NK cell function were identified ([@B42],[@B43], [@B48]; [@B79]). They were shown to function as inhibitory receptors specific for distinct HLA-C alleles ([@B48]). Molecular cloning revealed novel members of the Ig superfamily characterized by two extracellular Ig-like domains (KIR2D) and by a cytoplasmic tail containing two immunoreceptor tyrosine-based inhibition motif (ITIM; [@B42],[@B43], [@B48]; [@B79]). Three Ig-like domain KIRs (KIR3D) were also identified ([@B18]). They recognize either a group of HLA-B alleles sharing the HLA-Bw4 supertypic specificity or certain HLA-A alleles.

Among the activating forms of KIRs, the specificity for HLA class I molecules has been unequivocally documented only for KIR2DS1 and KIR2DS4 (**Table [1](#T1){ref-type="table"}**; [@B47]; [@B72]; [@B13]; [@B27]). KIRs are clonally distributed on NK cells and individual cells express different sets of inhibitory or activating KIRs. Notably, most (but not all) NK cells express at least one self-reacting inhibitory receptor, either a KIR or CD94/NKG2A ([@B45]).

While in an autologous setting NK cells can kill only cells that do not express sufficient HLA class I molecules ([@B16]), in a non-self environment NK cells may kill allogeneic cells. It became evident that such "alloreactive" NK cells could kill allogeneic cells, both *in vitro* and *in vivo*, when they expressed inhibitory KIRs that did not recognize HLA class I alleles on target cells ([@B15], [@B16]; [@B48]; [@B57]). In addition, these alloreactive NK cells should not express CD94/NKG2A^+^ ([@B57]) because HLA-E molecules are present in all HLA class I^+^ cells.

Notably, other factors may greatly contribute to NK alloreactivity. In particular, killing of target cells may also depend on the surface density of certain activating receptors (such as NCRs) on NK cells and on the expression of their ligands on target cells ([@B22]; [@B57]). More importantly, activating KIRs (in particular KIR2DS1) were shown to play a substantial role in mediating alloreactivity ([@B13]; [@B55]). KIR2DS1 activating receptor recognizes the C2 specificity ([@B13]). It is worthy to note that, in NK cells derived from C1/C2 or C1/C1 donors, activation via KIR2DS1 may overcome also the KIR2DL2/3-mediated inhibition, resulting in an efficient lysis of C2/C2 leukemic cells ([@B55]). In addition, KIR2DS1 can overcome the CD94/NKG2A-mediated inhibition, again resulting in killing of C2/C2 leukemias. Thus, the expression of KIR2DS1 may reveal NK cells endowed with potent alloreactivity and allow a more precise definition of the size of the alloreactive NK cell subset ([@B55]).

IDENTIFICATION OF ALLOREACTIVE NK CELLS
=======================================

Phenotypic identification of the alloreactive NK cell subset and assessment of the NK cytolytic activity against leukemic cells represent important criteria in donor selection. Multi-color flow-cytometric analysis using appropriate combinations of monoclonal antibodies (mAb) allows the identification and definition of the size of the alloreactive NK cell population ([@B13]; [@B55]). Substantial progress has been made recently after the identification of mAbs discriminating between inhibitory and activating KIRs. Thanks to these mAbs, it is now possible to distinguish KIR3DL1 from KIR3DS1, KIR2DL1 from KIR2DS1, and KIR2DL3 (but not KIR2DL2) from KIR2DS2 ([@B55]). This is most important because the expression of activating KIRs, in particular KIR2DS1, recognizing alleles belonging to the C2 specificity may exert a positive effect and greatly contribute to NK alloreactivity, provided that patient's cells express C2 alleles. Notably, the beneficial effect is more evident in leukemia blasts of pediatric acute lymphoblastic leukemia (ALL) that express higher levels of HLA class I molecules than AML blasts. In addition, the presence of activating KIRs can also be assessed by analyzing the KIR genotype and using appropriate redirected killing assays ([@B13]). Cytolytic activity of donor NK cells against patient's leukemic blasts or, alternatively, against appropriate EBV-induced B cell lines should be evaluated to select the HSCT donor with the best alloreactive capacity. In general, the degree of cytolytic activity correlates with the size of phenotypically defined alloreactive NK cell subsets ([@B13]; [@B55]).

The fact that alloreactive NK cells are generated in the recipient after the allograft was documented in the early studies by [@B67]. More recent studies by our group have confirmed and extended these findings. Donor's alloreactive NK cell populations have been identified on the basis of both phenotypic and functional (i.e., cytolytic activity) criteria in a large cohort of pediatric patients with high-risk leukemias even over 5 years after transplantation ([@B46], [@B51]). In these studies, a great variability in the size of the alloreactive NK cell population was detected in different donors and in post-transplantation patients. Importantly, most patients characterized by high proportions of alloreactive NK cells were disease-free after long time intervals ([@B55]). In addition, a correlation between the size of the alloreactive NK subset and the clinical outcome was found. After transplantation of positively selected CD34^+^ cells, KIR^+^ alloreactive NK cells were detectable at 6--7 weeks after transplantation and, in most instances, the pattern of expressed KIRs was similar to that originally found in the donor ([@B46], [@B51]; [@B55]).

A major and fascinating question is why alloreactive NK cells do not mediate GvHD. Early experimental evidence suggested that NK cells predominantly attack the hematopoietic cells of the host, while sparing tissues that are common targets of T cell-mediated GvHD. For example, in the hybrid resistance phenomenon in the mouse, NK cells rejected BM graft, but did not attack other tissues ([@B6]). More recent studies in mice showed that allogeneic cells can mediate GvL effect in the absence of GvHD ([@B2]). [@B67] obtained direct evidence that murine alloreactive NK cells did not cause GvHD, whereas infusion of allogeneic T cells killed all the mice. In the same murine model, alloreactive NK cells were also shown to kill host antigen-presenting cells. This effect can contribute to reduce the risk of GvHD. The molecular basis of the resistance of recipient normal tissues other than the hematopoietic ones is the lack of ligands for activating NK receptors. These ligands become expressed or up-regulated by cells of different histotypes upon cell stress, viral infection, or tumor transformation ([@B49]). Accordingly, NK cells cannot attack normal resting cells.

Notably, recent reports have proposed a novel approach for optimal donor selection based on the KIR genotype analysis. These studies provide evidence that the selection of donors with KIR B haplotypes was associated with significant improvements in both overall and relapse free survival, suggesting that activating KIRs, particularly those located in the centromeric portion, play a positive role in GvL in adult AML patients ([@B19]; [@B73]).

It should be mentioned that some studies failed to establish an association between the presence of donor NK alloreactivity and a favorable clinical outcome of transplanted patients ([@B34]; [@B53]; [@B75]). This can be explained taking into account (1) the type of grafted cells (manipulated vs un-manipulated), (2) the type of conditioning regimen, (3) the source (PBSC vs BM) and, importantly, the number of stem cells used ("megadoses" in haplo-HSCT), (4) the type of GvHD prophylaxis, and (5) the clinical status of the patient at the time of the allograft (early vs advanced disease).

RECENT ADVANCES AND FUTURE PERSPECTIVES
=======================================

There is no doubt that studies on NK cell receptor specificity and function allowed a rapid exploitation of these results in the treatment of high risk leukemias. Nonetheless, further relevant progresses are expected from the use of donor alloreactive NK cells as a tool for improving the clinical outcome of severe malignancies and for preventing GvHD.

The capability of alloreactive NK cells to kill host DCs, which are known to initiate T cell-mediated GvHD through presentation of host alloantigens to donor T cells, suggested a novel and interesting experimental approach in mice ([@B2]; [@B69]). Infusion of mature, donor-vs-recipient alloreactive NK cells prevented GvHD to such an extent that mice that were given these cells could receive mismatched BM grafts containing up to 30 times the lethal dose of allogeneic T cells in the absence of clinical or histological evidence of GvHD ([@B2]). Transfer of such an approach to humans is particularly promising to prevent or treat GvHD, in view of the role of the lytic activity of donor-derived NK cells toward recipient T lymphocytes in the control/prevention of graft rejection.

As mentioned above, in the haplo-HSCT setting, after the infusion of pure CD34^+^ cells, the first appearance of KIR^+^ alloreactive NK cells from HSC precursors may require 6--8 weeks and thus their anti-leukemia effect is relatively delayed. In case of high residual tumor burden and/or of rapidly proliferating leukemia blasts, this may result in leukemic relapses. To minimize this risk, mature alloreactive NK cells isolated from the haploidentical donor may be infused at short time intervals after HSCT. These mature donor NK cells could be properly activated *ex vivo* with interleukin-15 for further improving the clinical results of haplo-HSCT. Another promising and even less cumbersome approach is represented by the use of a recently developed method of graft manipulation based on the negative selection of T lymphocytes carrying the α/β chains of the T cell receptor (TCR) coupled with a B cell-depletion through an anti-CD19 mAb. T lymphocytes carrying the α/β chains of TCR are the lymphocyte subset responsible for the occurrence of GvHD, and thus their elimination allows to prevent the occurrence of this life-threatening complication of an allograft. This novel approach permits to transfer to the recipient not only high numbers of CD34^+^ cells, but also of mature donor NK cells and TCRγ/δ^+^ T cells which can display their protective effect against leukemia re-growth and life-threatening infections ([@B12]; [@B30]). Alloreactive NK cells are immediately available and may promptly exert their anti-leukemic and GvHD-preventing effect (**Figure [1](#F1){ref-type="fig"}**). A formal clinical trial using this approach is ongoing in our department and the preliminary results are extremely encouraging (Locatelli et al., unpublished). Likewise, preliminary experimental data indicate that, already 1 month after the allograft, pediatric patients receiving this novel type of HSCT from an HLA-haploidentical donor have peripheral mature NK cells that fully express KIRs and are endowed with a good lytic capacity against leukemia cells.

![**A novel strategy for HSC transplantation from haploidentical donors**. In this protocol, HSC-enriched cell populations are obtained by negative selection upon removal of TCR α/β^+^ T cells and CD19^+^ B cells. Notably, in addition to CD34^+^ cells, these cell suspensions contain mature NK cells and TCR γ/δ^+^ T cells. Using this strategy, two sources of alloreactive NK cells will come into play: (1) those generated from CD34^+^ cells after 6--8 weeks from transplantation and (2) those present in the fresh cell suspension infused into patients. It is evident that the prompt availability of alloreactive effector cells may greatly improve the anti-leukemia effect and the removal of residual patient's DCs and T lymphocytes, thus ensuring a more efficient prevention of leukemic relapses, GvHD and graft-rejection. In addition, transplanted NK and γ/δ T cells may provide a first line of defense against different infectious agents.](fimmu-04-00015-g001){#F1}

Regarding other possible settings in which alloreactive NK cells can be of relevant clinical interest, recent studies reported on the infusion of third-party purified NK cells in patients with either relapsed or first CR AML, who had not received allogeneic HSCT ([@B40]; [@B66]). These patients were given immunosuppressive chemotherapy (combining fludarabine and cyclophosphamide) and interleukin-2, respectively, before and after NK cell infusion in order to prevent rejection and favor NK cell function. NK cells transiently engrafted and expanded *in vivo*. The clinical results were particularly encouraging. This appears as a promising novel therapy for reducing the risk of relapse in patients with AML treated with conventional chemotherapy. Another promising approach to control leukemia progression resides in the NK cell manipulation using anti-KIR mAb ([@B65]). This mAb, currently tested in phase II clinical trials on patients with AML or multiple myeloma, confers specific, stable blockade of KIR and induces NK-mediated killing of HLA-matched tumor cells *in vitro* and *in vivo*.

Altogether these data indicate that the discovery of NK receptors and NK cell alloreactivity has represented a true revolution in the field of allo-HSCT, underlining that not only adaptive immunity, but also innate immunity may be crucial for guaranteeing a successful clinical outcome.
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